Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking

Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiakolas, Andrea R., Kramer, Kevin J., Johnson, Nicole V., Wall, Steven C., Suryadevara, Naveenchandra, Wrapp, Daniel, Periasamy, Sivakumar, Pilewski, Kelsey A., Raju, Nagarajan, Nargi, Rachel, Sutton, Rachel E., Walker, Lauren M., Setliff, Ian, Crowe, James E., Bukreyev, Alexander, Carnahan, Robert H., McLellan, Jason S., Georgiev, Ivelin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378442/
https://www.ncbi.nlm.nih.gov/pubmed/35241839
http://dx.doi.org/10.1038/s41587-022-01232-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378442/
https://www.ncbi.nlm.nih.gov/pubmed/35241839
http://dx.doi.org/10.1038/s41587-022-01232-2

Ejemplares similares